.
MergerLinks Header Logo

New Deal


Announced

Completed

AyurMaya led a $45m Series C round in Koneksa.

Financials

Edit Data
Transaction Value£37m
Consideration TypeCash
Capital Owned-
Capital Bid For-
EV/Sales-
EV/EBITDA-
Share Price Premium-
One Off Charge-

Sources

Edit

Tags

Edit

digital biomarkers

Friendly

United States

Completed

wearables

Domestic

Private Equity

Acquisition

Minority

Medical Equipment

Private

Biotechnology

Single Bidder

drug development

Synopsis

Edit

AyurMaya, an affiliated fund of Matrix Capital Management, led a $45m Series C funding round in Koneksa, a digital biomarkers maker, with participation from Takeda Ventures, Velosity Capital. McKesson Ventures, Merck Global Health Innovation Fund, Novartis (dRx Capital), Spring Mountain Capital and Waterline Ventures. “We contribute to better lives by building health measurements that matter. I’m delighted to welcome John Wagner, one of our earliest collaborators and an industry pioneer to our leadership team. We look forward to accelerating development of our biomarker technology platform and expanding our team to deliver more efficient clinical trials," Chris Benko, Koneksa CEO.

Search a database of more than 250,000 verified dealmakers

Receive automated updates on global transactions

Follow the activity, relationships and transactions of top dealmakers

No credit card required

© COPYRIGHT 2024 MERGERLINKS LIMITED.

ALL RIGHTS RESERVED.

15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.

CONTACT US